Table 1.
Group | Immunogen | Survival | Antibody titer (EC50)
|
Neutralization titer (ED50)
|
Detectable LF IgG/IgM | Inhaled spore dose | ||
---|---|---|---|---|---|---|---|---|
Pre-challenge | Post-challenge | Pre-challenge | Post-challenge | Post-challenge | (LD50 ± SD) | |||
1 | BT-LND(2) | 7/7a | 38,427 | 32,949 | 1813 | 4876 | 1/7 | 204 ± 43 |
2 | TB-LND(2) | 7/7a | 57,185 | 51,381 | 4764 | 8,751b | 0/7 | 195 ± 46 |
3c | PA | 7/7a | 82,651 | 76,336 | 1954 | 836d | 0/7 | 196 ± 44 |
4c | Control MAP | 0/9 | ND | ND | ND | ND | ND | 186 ± 52 |
5c | Naïve | 0/6 | ND | ND | ND | ND | ND | 202 ± 45 |
Pre- and post-challenge titers shown are geometric mean titers.
p < 0.0001, compared to Naïve, Mantel–Cox log-rank test.
p = 0.031, Wilcoxon matched-pairs signed rank test.
Control groups reported previously.
p = 0.016, Wilcoxon matched-pairs signed rank test.